Ligand initiated with a Buy at BofA
BofA initiated coverage of Ligand (LGND) with a Buy rating and $244 price target Citing a portfolio of more than 100 high-value commercial and development assets, increasing needs for flexible, non-dilutive capital in the industry and a lean cost structure, the analyst contends that the biopharma royalty firm can continue to deliver on its “aggressive earnings targets.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
See Insiders’ Hot Stocks on TipRanks >>
Read More on LGND:
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Can the Best Crypto Presale Turn $4K Into $182K? Investors Watch APEMARS And Top 6 Altcoins In 2026 Shift

5 Top Cryptos To Invest In For Maximum Gains: Is APEMARS Leading The Market News Today With Over 1,795+ Holders

Something Is Brewing In XRP’s On-Chain Data. Here’s the Latest
Senator Elizabeth Warren Attacks Ripple (XRP) Again. Here’s the Latest
